The future of combination treatment with checkpoint inhibitors in melanoma
Sullivan, R.J.
Clinical Advances in Hematology and Oncology H&o 17(2): 96-99
2019
ISSN/ISBN: 1543-0790 PMID: 30845111 Document Number: 698787
Document emailed within 1 workday
Related Documents
Eto, M. 2017: New Treatment Options for Renal Cell Carcinoma - Efficacy and Safety of Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(8): 667-673Cooling, L.L.; Sherbeck, J.; Mowers, J.C.; Hugan, S.L. 2017: Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation Immunohematology 33(1): 15-21
Chen, W.J.Y.; Krul-Poel, Y.H.M.; Roth, C.; Labots, M.; van den Eertwegh, A.J.M.; Dreijerink, K.M.A. 2019: Endocrine side effects of checkpoint inhibitors Nederlands Tijdschrift Voor Geneeskunde 163
Miyawaki, E.; Kenmotsu, H. 2018: Pneumonitis Induced by Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(7): 1021-1026
Jaafar, J.; Mavromati, M.; Philippe, J. 2018: Endocrinopathies induced by immune checkpoint inhibitors Revue Medicale Suisse 14(588-589): 34-38
Trivedi, M.S.; Hoffner, B.; Winkelmann, J.L.; Abbott, M.E.; Hamid, O.; Carvajal, R.D. 2015: Programmed death 1 immune checkpoint inhibitors Clinical Advances in Hematology and Oncology: H&o 13(12): 858-868
Li, B.; Chan, H.Lam.; Chen, P. 2019: Immune Checkpoint Inhibitors: Basics and Challenges Current Medicinal Chemistry 26(17): 3009-3025
Fuse, M.; Yoshimura, K. 2017: The development status of the next-generation immune checkpoint inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 75(2): 245-250
Inaba, H.; Ariyasu, H.; Kurimoto, C.; Iwakura, H.; Akamizu, T. 2018: Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(7): 1031-1035
McArthur, H.L. 2016: Checkpoint inhibitors in breast cancer: hype or promise? Clinical Advances in Hematology and Oncology: H&o 14(6): 392-395
Jørgensen, L.B.; Bastholt, L.; Yderstræde, K. 2017: Immune checkpoint inhibitors and endocrinological side effects Ugeskrift for Laeger 179(49)
Fløe, L.E.ær.; Svane, I.M.; Bastholt, L.; Schmidt, H. 2016: Immune checkpoint antibodies increase survival in patients with metastatic melanoma Ugeskrift for Laeger 178(33)
Brahmer, J.R. 2016: Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer Clinical Advances in Hematology and Oncology: H&o 14(3): 165-167
Muro, K. 2016: Potentiality of Immune Checkpoint Inhibitors for Advanced Esophageal and Gastric Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(9): 1041-1047
Fontecilla, N.M..; Khanna, T.; Bayan, C.-A.Y..; Antonov, N.A..; Geskin, L.J.. 2019: Bullous Pemphigoid Associated with a new Combination Checkpoint Inhibitor Immunotherapy Journal of Drugs in Dermatology: Jdd 18(1): 103-104
Webb, P.; Rice, T.W.; Cooksley, T. 2017: Problem-based review: Immune-mediated complications of 'Checkpoint Inhibitors' for the Acute Physician Acute Medicine 16(1): 21-24
Owada-Ozaki, Y.; Nishiyama, K.; Kobayashi, T.; Suzutani, T.; Suzuki, H. 2018: A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(9): 1234-1237
McClay, E.F.; Mastrangelo, M.J.; Bellet, R.E.; Berd, D. 1987: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma Cancer Treatment Reports 71(5): 465-469
Terada, R.; Ito, S.; Kobayashi, M.; Akama, F.; Tsujimura, M.; Ooe, H. 2002: Anorectal melanoma: successful treatment by surgical excision and combination chemoimmunotherapy Hepato-Gastroenterology 49(48): 1545-1548
Kawamori, R. 2011: The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus Nihon Rinsho. Japanese Journal of Clinical Medicine 69(8): 1515-1519